We have studied the effects of endogenous and exogenous estrogen on atherosclerotic lesions in apolipoprotein E-deficient mice. Female mice ovariectomized (OVX) at weaning displayed increases (P < 0.01) in fatty streak lesions in the proximal aorta and aortic sinus compared with female mice with intact ovarian function. These differences between the OVX and sham controls were apparent in both chow-and "Western-type" diet-fed mice. Moreover, increases in lesion size following OVX occurred without changes in plasma cholesterol. Hormone replacement with subdermal 17-8-estradiol pellets releasing either 6, 14, or 28 jig/day significantly decreased (P < 0.001) atherosclerotic lesion area in both male and OVX female mice. In contrast, neither 17-a-estradiol (28 ,ig/day) or tamoxifen (85 ,ig/day) affected lesion progression in OVX female mice. In the Western diet-fed group, exogenous estradiol markedly reduced plasma cholesterol and triglycerides, whereas, in animals fed the chow diet, exogenous estrogen and tamoxifen treatment only decreased plasma and very low density lipoprotein triglycerides. However, lesion area was only weakly correlated with plasma cholesterol and triglycerides, 0.35 and 0.44 tau values, respectively (P < 0.01). In summary, in the apolipoprotein E-deficient mouse 17-j8-estradiol protects against atherosclerotic lesion formation, and this can only be partially explained through effects on plasma lipoprotein levels. Cardiovascular diseases resulting from atherosclerosis are a leading cause of death in Western societies (1). Epidemiological studies show men and postmenopausal women are at higher risk for such diseases than are premenopausal women, suggesting that estrogen may be cardioprotective (2, 3). This reduction in risk for cardiovascular disease is caused in part by the effects of estrogen on lipoprotein metabolism and shifts of the plasma lipoproteins to a less atherogenic profile (4). Estrogen, particularly when taken orally, lowers plasma low density lipoprotein (LDL) and raises high density lipoprotein (HDL) levels (5, 6). Although these lipoprotein changes occur in premenopausal women and postmenopausal women receiving hormone replacement therapy, in large-scale studies with adjustments for multiple risk factors, only 25-50% of the beneficial effects of estrogen appear to be due to lipoprotein effects (7).
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Cardiovascular diseases resulting from atherosclerosis are a leading cause of death in Western societies (1) . Epidemiological studies show men and postmenopausal women are at higher risk for such diseases than are premenopausal women, suggesting that estrogen may be cardioprotective (2, 3) . This reduction in risk for cardiovascular disease is caused in part by the effects of estrogen on lipoprotein metabolism and shifts of the plasma lipoproteins to a less atherogenic profile (4) . Estrogen, particularly when taken orally, lowers plasma low density lipoprotein (LDL) and raises high density lipoprotein (HDL) levels (5, 6) . Although these lipoprotein changes occur in premenopausal women and postmenopausal women receiving hormone replacement therapy, in large-scale studies with adjustments for multiple risk factors, only 25-50% of the beneficial effects of estrogen appear to be due to lipoprotein effects (7) .
The nonlipid effects of estrogen that may contribute to the cardioprotection observed in humans include the following: effects on endothelial metabolism (8, 9) , myocardial conductance, hemostatic factors (10, 11) , vascular tone and reactivity (12) , intimal cell proliferation (13, 14) , Lp(a) levels (15) , expression of adhesion molecules (16) , platelet aggregation (17) , LDL oxidation (18, 19) , inflammatory cytokine expression (20, 21) , and extracellular matrix synthesis. Additionally, estrogen might affect arterial wall calcification (22) , the formation of unstable plaque and the generation of occlusive thrombi (4) .
Detailed systematic evaluation of these parameters in vivo requires an appropriate and convenient animal model.
Several large animal species including nonhuman primate (23), swine (19) , and rabbits (24) have been used to study the effects of estrogen on atherosclerotic lesion development. However, due to variability in lesion formation, large numbers of animals are required for such studies, making them difficult and expensive. Homologous recombination techniques targeting the apolipoprotein E (apoE) gene have recently generated mice that develop atherosclerosis, providing a convenient source of large numbers of animals in which to study atherogenesis (25, 26) . These apoE-deficient mice reproducibly develop hypercholesterolemia with progressively complex and widespread lesions resembling inflammatory-fibrous plaques seen in humans (25) . To explore whether endogenous or exogenous estrogen can protect against atherosclerosis development in the apoE-deficient mouse, we examined the effect of ovariectomy and estrogen replacement therapy on lesion size and plasma lipoproteins under a variety of dietary conditions in this animal model.
MATERIALS AND METHODS
Animals. Homozygous apoE-deficient mice were bred in house and used for the atherosclerotic studies. These mice have a mixed genetic background (129o1a x C57B/6), and animals from each experiment were derived from brothersister matings as described (25) . Mice were maintained in a 12-hr light/dark cycle room with free access to food and water. Mice were fed either chow (PROLAB 3000, containing 5% fat; Agway, Syracuse, NY) or an adjusted calories "Western-type" diet (TD 88137, containing 21% fat and 0.15% cholesterol by weight; Harlan Teklad, Madison, WI). At weaning (age 28 days), female mice were bilaterally ovariectomized (OVX) or sham operated through a 1-cm dorsal incision. At 45 days of age, the mice were randomly assigned to treatment groups and slow-release pellets (Innovative Research of America) were inserted interscapularly under anesthesia, as follows: 0.5 mg placebo, or one of three doses of 17-,B-estradiol pellets, prepared to dispense either 6 ,ug/day (,BE1), 12 jig/day (13E2), or 28 ,ug/day (,BE3) and generating plasma estradiol concentrations from 100 to 900 pg/ml. Time-release pellets for 17-a-estradiol delivered 28 ,ug/day (>900 pg/ml), and tamoxifen pellets delivered 80 ,ug/day (4 ng/ml). The lower dose of 17-f3-estradiol (6 ,ug/day; ,BE1) was expected to maintain estradiol around 100 pg/ml, which is within the range of sham Tissue Preparation. After an overnight fast, mice were anesthetized with ketamine/xylazine (Miles). Blood and uteri were removed followed by in situ perfusion (80 mm Hg) with phosphate-buffered saline (PBS), pH 7.4.
To prepare sections for lipid staining and morphometric analysis, hearts were perfusion fixed in situ with either 10% buffered formalin or 4% paraformaldehyde. The heart and aorta were removed and fixed for an additional 2-3 hr in either 10% buffered formalin or 4% paraformaldehyde followed by infiltration with 30% gum sucrose (1% gum arabic plus 30% sucrose in PBS) for 24 hr at 4°C. To determine cross-sectional lesion area, hearts were embedded in OCT compound and cryostat-sectioned at 10 ,um at -18°C. Every other section was mounted on slides coated with Vectabond (Vector Laboratories). The area of the heart to be sectioned was divided into two separate regions commonly used for quantitating the degree of atherosclerotic lesions in mice, the aortic sinus (28) and the aortic valve (29) . Moving up from the base of the heart, the sinus begins at the first appearance of the valve cusps dividing the lumen into three distinct regions. In this region, the aortic wall is bulging and irregular. The sinus region ends and the valve region begins when the valve cusps no longer divide the lumen and the wall appears more rounded and distinct. The valve begins at the end of the sinus and continues until the valve cusps are no longer apparent and the wall is well rounded (-e280 ,um The percent of the aortic surface covered by lesions was determined using an en face preparation. Aortas infiltrated with gum sucrose as described above were cleaned of adventitia, and a longitudinal cut was made from the arch down toward the femoral branch. A second longitudinal cut was made between the coronary and carotid arteries in the aortic arch, and the aorta was laid open on a piece of polystyrene. Each aorta was evaluated for lesion area by direct image capture from a charge coupled device camera attached to a copy stand and displayed on a Trinitron monitor. The lesion area was determined in unstained tissue using OPTIMAS 4.1 image analysis. Areas of atherosclerotic plaques in aortas cleaned of adventitia appear as yellowish-white areas. This area was quantitated by manually setting thresholds for shades of black (background), gray (normal tissue), and white (lesion area).
Immunohistochemistry. Hearts were also embedded in paraffin following fixation with methanol-Carnoy's (60% methanol, 30% chloroform, and 10% acetic acid) for 4 hr at 4°C, and 5-gm sections were stained for elastin using Verhoeffs stain.
Smooth muscle cells were identified with a mouse monoclonal anti-actin immunoglobulin (5 Ag/ml; Boehringer Mannheim), which was followed by an alkaline phosphatase-conjugated donkey anti-mouse IgG (1:300; Jackson ImmunoResearch).
Plasma Lipoproteins and Lipids. Separation of plasma lipoproteins using fast protein liquid chromatography (FPLC; Pharmacia LKB) was performed as described (30) . Total plasma cholesterol and triglycerides were measured using colorimetric methods with commercially available kits (Wako Biochemicals, Osaka, and Boehringer Mannheim).
Statistical Analysis. Analysis of variance (ANOVA) was used to test for statistically significant differences between the groups with regard to diet, treatment, age, serum lipids, physiological status (OVX/sham), and lesion size. Fisher's F test was used to determine significant differences among means. Correlation studies were done using Kendall's ranked correlations tau test. Significant differences between the coefficient of variation of the data expressed as an area or as a percentage was determined using a paired Student's t test.
RESULTS
Analysis of Plasma Lipids and Lipoproteins. The contribution of plasma lipids to lesion progression was assessed in apoE-deficient mice with altered ovarian function and receiving hormone replacement. As expected, ovariectomy prevented uterine hyperplasia, as evidenced by uterine weight, and caused a slight but nonsignificant elevation in body weight (Table 1) . Endogenous estrogen delivered through intact ovarian function compared with OVX animals had no effect on plasma cholesterol in mice fed either a chow or Western-type diet. However, exogenous estrogen delivered as 17-03-estradiol (6, 12, or 28 ,ug/day) via subcutaneous time-release pellets decreased plasma cholesterol 22-34%, depending on diet (Table 1) . Endogenous estrogen and treatment with 17-,Bestradiol (6-28 ,ug/day) lowered plasma triglycerides to a similar extent in both chow-fed and fat-fed mice (Table 1) . Size separation of plasma lipoproteins using FPLC demonstrated that, in apoE-deficient mice, 75% of the plasma lipids are carried in large particles corresponding to very low density lipoprotein (VLDL). Fig. 1 shows FPLC lipoprotein elution profiles for mice fed a Western-type diet. Estrogen specifically decreased cholesterol and triglycerides in the VLDL fraction.
Qualitatively similar FPLC plasma lipoprotein profiles were obtained from chow-fed mice, and the total cholesterol content of each lipoprotein peak is shown in Table 2 . Exogenous estradiol (12 ,ug/day) and tamoxifen (80 ,ug/day) treatment specifically decreased cholesterol in the VLDL fraction, with no significant changes occurring in the smaller lipoprotein fractions corresponding to LDLs and HDLs.
Estrogen Effects on Atherosclerotic Lesions. The elimination of circulating ovarian steroids by bilateral ovariectomy resulted in a significant increase in atherosclerotic lesions (Table 3) . ApoE-deficient mice spontaneously develop lesions in the aortic valve and throughout the arterial tree. As shown in Fig. 2 , lesions were observed throughout the aorta in all groups and lesions were less extensive in sham mice ( Fig. 2A ) compared with OVX mice (Fig. 2B) . Lesion areas in the aorta were also reduced in 17-,3-estradiol-treated mice (Fig. 2D) .
Endogenous and exogenous estrogen also reduced the extent of lesions throughout the aortic valve. The specific area of the aortic valve reported for lesion assessment has differed among several laboratories (28, 31) . Therefore, lesions were quantitated in the two distinct regions (sinus and valve) described by Paigen et al. (29) . The very thin medial layer and irregular shape of the sinus distinguishes it from the more rounded and distinct wall of the valve region. Mean lesion area measurements were not significantly different between these two regions, and the measurement was highly correlated (tau = 0.85). Measurements of lipid staining as a percentage of the total arterial wall area were corrected for variations in heart size and artifacts of fixation, thereby reducing variability. The coefficient of variation within groups was reduced (P < 0.01) in the sinus region from 56% to 40% and in the valve region from 59 to 43%. Thus, the percent lesion area was significantly reduced (P < 0.01) in sham versus OVX control animals on either diet (Table 3 ).
The accelerated progression of lesions resulting from ovariectomy was completely reversed with 17-f3-estradiol treatment (Fig. 3) . OVX mice treated for 90 days with each of three levels of 17-,B-estradiol showed marked reductions in lesion area in the aortic sinus, valve, and proximal aorta (Table 3 ). This effect of estradiol on lesion progression was specific for the 17-/3-stereoisomer of estradiol, which displays high affinity for the estrogen receptor. High levels of 17-a-estradiol (28 ,ug/day for 90 days), a stereoisomer with low affinity for the estrogen receptor, had no significant effect (P > 0.5) on lesion size or plasma lipid concentrations. Estrogen Treatment in Male ApoE-deficient Mice. Homozygous apoE-deficient males also develop advanced raised fibroproliferative lesions (Fig. 4) . Although circulating estrogen levels are several thousand-fold higher in females with intact ovarian function, males express comparable levels of estrogen receptor. Therefore, we compared the effects of exogenous estrogen on lesion progression in both sexes. Consistent with studies in females, 17-j3-estradiol treatment for 90 days significantly reduced lesion area and lesion progression in male mice (Table 4) . Advanced lesions were commonly observed in untreated mice and characterized by fibrous cap formation ( Fig. 5 ) with deep medial involvement and elastic fragmentation (Fig. 6) . Lesion size was similar in males compared with age-matched females (Table 4) .
Effects of Tamoxifen. Since tamoxifen has both antiestrogenic and estrogenic properties depending on species and tissue type, we directly compared the effects of 17-,B-estradiol (12 ,ug/day) to tamoxifen (80 ,ug/day) in both male and female mice. The uterine weights of tamoxifen-treated OVX female mice were the same as controls (data not shown). Tamoxifen decreased plasma triglycerides to the same extent in both males and females (Table 4) . Despite this estrogen-like effect on plasma lipids, tamoxifen treatment had no significant effect on atherosclerotic lesion area in either male or female mice (Table 4) . Relationships between Plasma Lipids and Lesion Size.
Exogenous 17-,3 estradiol reduced lesion size in chow-fed OVX mice comparable to those seen in sham-operated animals. However, in Western-type diet-fed mice, administration of 17-,B estradiol in amounts that exceeded endogenous levels reduced lesion size in the aortic sinus, valve, and aorta to less than one-third of the size in sham controls. The greater degree of cardioprotection provided by exogenous estrogen in mice fed a Western-type diet (Table 3 ) appeared to be related to the added effect of estrogen to reduce plasma lipid levels by 50%. Although there were obvious differences among groups of animals fed the different diets, the relationships between plasma lipid levels and lesion development were low among individual mice, reflecting the considerable variability of these parameters. When data were analyzed in a combined data set including animals on various diet and treatment groups, plasma cholesterol values were somewhat predictive in both the sinus and valve regions (tau = 0.37 and 0.36, respectively; P < 0.01), but not significantly related (P < 0.4) to lesion area in the aorta (tau = 0.051). Plasma triglycerides were weakly related to all three lesion measurements to an equal extent (tau = 0.32; P < 0.01).
DISCUSSION
Estrogen delivered through intact ovarian function or as 17-,3-estradiol via subcutaneous time-release pellets significantly decreased the progression of atherosclerotic lesions in homozygous apoE-deficient male and female mice. Through the use of different diets and estrogenic compounds with known differences in estrogen receptor binding affinities, we have demonstrated that the effects on lesion size were specific to 17-,B-estradiol. Moreover, our findings with the apoEdeficient mice are consistent with epidemiological data and large clinical trials in postmenopausal women, suggesting that the cardioprotective effects of estrogen are not fully explained by changes in serum lipids and lipoproteins (7, 32) .
The advantages of a small, genetically defined murine model in which to study the pathogenesis of atherosclerosis have been reviewed (33 (34) . In these mice, nearly 75% of plasma lipids are contained in VLDL-sized particles, and this distribution is independent of diet. Plasma HDL cholesterol and apolipoprotein A-I are equivalent in both sexes (35) . More importantly, we show both male and female apoE-deficient mice are susceptible to atherosclerosis and responsive to estrogen treatment. Our findings extend the use of this transgenic murine model to studies involving both the indirect and the direct effects of estrogen on the atherosclerotic process. In our studies, estrogen was shown to decrease plasma and VLDL triglycerides. This decrease could occur through various proposed mechanisms for estrogen action, including the following: effects on VLDL production and/or clearance rates (5, 6, 36) ; reduction in hepatic lipogenesis (37) ; increased LDL receptor expression (38, 39) ; and increased lipoprotein lipase activity (40) . Increases in hepatic clearance of VLDL in the apoE-deficient mouse would require a mechanism independent of apoE, the primary apolipoprotein determinant for hepatic VLDL clearance (41) . Increased lipolytic activity is suggested by the reduced VLDL/protein ratio observed in the estrogen-treated mice. However, additional studies are needed to clarify the effects of estrogen on triglyceride processing. Previous attempts to model the cardioprotective effects of estrogen in the mouse have had limited success. Atherosclerosis can be induced in susceptible C57BL/6 mice fed diets high in both cholesterol and cholic acid (42) , but the fatty lesions are small, highly variable, and histologically distinct from the complex, staged lesions found in humans. In C57BL/6 mice, most plasma cholesterol and cholesteryl-esters are contained in HDL particles, and cholesterol/cholic acid feeding selectively decreases HDL concentrations in female mice (43 (35, 44) . Our studies, in which variability in lesion size was relatively low, found no difference in lesion size between males and females.
The ability of anti-estrogens, such as tamoxifen, which compete with estradiol for estrogen receptor binding, have been useful tools for studying the physiological and behavioral aspects of estrogen (45) . However, one must be careful with literature interpretation, as tamoxifen can behave as both an estrogen antagonist and/or agonist depending on species, tissue type and estrogen-sensitive endpoints measured (45, 46) . Although the effects of tamoxifen have been studied extensively in rats in relation to energy balance (47), estrous behavior, and uterotropic behavior (48) , few studies have been conducted in mice concerning lipoprotein metabolism and atherosclerosis.
The effects of oral tamoxifen have been studied in male C57BL/6 mice in which atherosclerosis is induced by a high cholesterol/cholic acid diet (49) . Tamoxifen was reported to suppress lesion formation, lower body weight, and raise plasma triglycerides (49) . Although we show subcutaneous tamoxifen treatment had similar effects on body weight changes, plasma triglycerides were lowered. Our studies also demonstrated that tamoxifen had no effect on spontaneous atherosclerotic lesions in either male or female chow-fed homozygous apoEdeficient mice. Moreover, 17-a-estradiol, which has a low affinity for the estrogen receptor also had no effect on lesion size in apoE-deficient mice. These data demonstrate that the murine models of atherosclerosis can provide valuable insight into the cardioprotective effects of estrogen and estrogen agonists. The data reported herein are consistent with the cardioprotective effects of estrogen observed in other species. Our findings in the apoE-deficient mouse further indicate that the beneficial effect of estrogen is only partially explained by changes in serum lipids and lipoprotein, thus implying a direct effect of estrogen on the arterial wall. The underlying mechanism remains to be elucidated, and the apoE-deficient mouse provides a useful model in which to examine and manipulate the genes and gene products responsible for contributing to the cardioprotective effects of estrogen.
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